title: Losartan improves diastolic ventricular filling of hypertensive patients with diastolic dysfunction.
abstract: To evaluate the role of losartan on left ventricular (LV) function of hypertensive patients. Hypertensive patients (n = 19) underwent evaluation of systolic and diastolic LV function, using radionuclide ventriculography (RVG), before and at 3 mo into the treatment with the angiotensin II antagonist losartan. All patients underwent a baseline 12 lead ECG and an echocardiogram (ECHO), which was also repeated at 3 mo into treatment. Results are expressed as mean +/- SEM and statistics were performed using paired t-test. A p value < or = 0.05 was considered significant. Treatment with losartan for 3 mo had no effect on LV mass measured by echo (141+/-5 vs. 139+/-6 g/m2). The LV ejection fraction, measured by RVG, was unchanged by treatment when compared to the baseline study (58+/-2% vs. 57+/-2%, respectivelly, p = 0.49). Considering all patients involved in the study (n = 19), the LV "Peak Filling Rate" (PFR), a parameter of diastolic function measured by RVG, was also unchanged by treatment when compared to baseline (2.5+/-0.2 EDV/s vs. 2.5+/-0.3 EDV/s, respectively, p = 0.9). However the analysis of those patients with evidence of diastolic dysfunction (n = 12) on the baseline RVG (PFR < 2.5 EVD/s), demonstrated significant improvement of LV filling after therapy with losartan (PFR = 1.8+/-0.1 EDV/s vs. 2.3 +/-0.2 EDV/s, respectively, p = 0.05). This change was associated with improvement of symptoms. Our results demonstrated that hypertensive patients with diastolic dysfunction on radionuclide ventriculography have significant improvement of ventricular filling at 3 mo into treatment with losartan.
authors.affiliation: Medical School of São José do Rio Preto, São Paulo, Brazil.
authors.forename: J C
authors.initials: JC
authors.lastname: Ayoub
authors.forename: J V
authors.initials: JV
authors.lastname: Vitola
authors.forename: A
authors.initials: A
authors.lastname: Parro
authors.forename: O M
authors.initials: OM
authors.lastname: Costa
authors.forename: A S
authors.initials: AS
authors.lastname: Delgado
authors.forename: A H
authors.initials: AH
authors.lastname: de Parma
authors.forename: I T
authors.initials: IT
authors.lastname: Takakura
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D004452:Echocardiography; D004562:Electrocardiography; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D019808:Losartan / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015635:Radionuclide Ventriculography; D013318:Stroke Volume; D018754:Ventricular Dysfunction / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D016276:Ventricular Function / Q000187:drug effects*
chemical_list: D000959:Antihypertensive Agents; D019808:Losartan